Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05860725 · ClinicalTrials.gov registry record · NA
Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy
A NA study of Human Papillomavirus Infection and Vaccination Hesitancy, sponsored by University of Virginia.
- Recruiting
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT05860725: Recruiting NA study of Human Papillomavirus Infection and Vaccination Hesitancy, sponsored by University of Virginia.
NCT05860725 is a NA study of Human Papillomavirus Infection and Vaccination Hesitancy that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 220 participants, below the 1,269-participant average among 22 other Human Papillomavirus Infection trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05860725, a NA study of Human Papillomavirus Infection and Vaccination Hesitancy, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
Since 2019, the HPV working group of the University of Virginia Cancer Center's Southwest Virginia Community Advisory Board has developed and executed strategies to increase regional HPV vaccination rates. Members collaboratively developed Appalachian Voices for Health, a multi-level media production and social marketing intervention. This novel intervention builds on the past efforts of the working group and the engaged organizations; takes into account the impact of vaccine hesitancy on HPV vaccination uptake; and incorporates best practices. Through the intervention, Nursing and Dental Assistant students from Mountain Empire Community College will develop PSAs after receiving training about HPV vaccination and health communication. These PSAs will be used in a social marketing campaign executed through a regional transportation system managed by Mountain Empire Older Citizens. Specifically, the trial's aims are three-fold: assess the intervention's impact on community members' and students' HPV vaccine hesitancy (Aim 1) and perceptions and actions related to HPV vaccination (Aim 2) and evaluate other feasibility indicators at the community-, student-, organizational-, and process levels (Aim 3). The research team will use a concurrent mix-methods approach to assess feasibility indicators. Aims will be assessed using surveys, focus groups, meeting minutes, and implementation records. Data will be analyzed using descriptive and inferential statistics and content coding. Determination of the intervention's feasibility will consider the achievement benchmarks for feasibility indicators individually and collectively. Data will be used to inform refinement and future testing of Appalachian Voices for Health.
Conditions Studied
Interventions
- BEHAVIORAL PSA Development
- BEHAVIORAL HPV vaccination focused social marketing campaign
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2024-05-30 |
| Phase | NA |
What NCT05860725 shows while recruiting
NCT05860725 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,269-participant average among 22 other Human Papillomavirus Infection trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 2 interventions - of which PSA Development is the first listed.
NCT05860725 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05860725 about?
NCT05860725 is a clinical study titled "Feasibility Trial of a Multi-level Media Production and Social Marketing Campaign to Reduce HPV Vaccine Hesitancy". Since 2019, the HPV working group of the University of Virginia Cancer Center's Southwest Virginia Community Advisory Board has developed and executed strategies to increase regional HPV vaccination rates. Members collaboratively developed Appalachian Voices for Health, a multi-level media productio...
What is the current status of trial NCT05860725?
This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2023-03-13. Estimated completion is 2024-05-30.
What conditions does trial NCT05860725 study?
This clinical trial studies the following conditions: Human Papillomavirus Infection, Vaccination Hesitancy.
What interventions are being tested in trial NCT05860725?
The interventions under investigation include: PSA Development (BEHAVIORAL), HPV vaccination focused social marketing campaign (BEHAVIORAL).
Who is sponsoring clinical trial NCT05860725?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05860725 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05860725's enrollment target sits among peer trials
220 15th of 22 higher than 8 of 22 other Human Papillomavirus Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Papillomavirus Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
RECRUITING · NA
-
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
-
Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement
ACTIVE NOT RECRUITING · NA
-
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI